Sale of existing shares in AlzChem Group AG in a private placement to institutional investors
Not for publication or distribution in the United States of America, Australia, Canada, Japan or South Africa or in any other jurisdiction in which offers or sales would be prohibited by applicable law.
October 17, 2018
Today, AlzChem Group AG‘s three majority shareholders, namely LIVIA Corporate Development SE, HDI Vier CE GmbH, and four two na GmbH, published their decision to place existing shares in AlzChem Group AG, increasing the free-float in AlzChem’s ordinary bearer shares from approximately 1.2% to between approximately 21.3% and 28.0%, depending on the full placement size.
“We are delighted that our core shareholders play an active role in supporting AlzChem to create and significantly improve the perception of our stock exchange listing. At the same time we highly appreciate their long-term commitment to AlzChem. The increased free float will contribute to a higher visibility on the capital markets and we are excited to enter a next chapter in our company’s history“, said Ulli Seibel, CEO of AlzChem Group AG.
In light of the current solid business development, the management of AlzChem Group AG confirms the forecast made for the calendar year 2018. Pursuant to the forecast, sales growth is forecasted in the mid-single-digit percentage range, which translates into revenues between EUR 364.5 to 378.7 million and EBITDA of EUR 49 to 54 million.
AlzChem Group AG is a vertically integrated manufacturer of various chemical products based on the NCN chain. These are products with typical nitrogen-carbon-nitrogen bonding that are used in a wide variety of different industries. The company has a leading position in select niche markets. The strategic focus of growth and the main focus of its extensive research and development are on the business segment Specialty Chemicals. The company has around 1,500 employees at four sites in Germany and three other sites abroad.
Disclaimer / Important Note
This release is for informational purposes only and does not constitute an offer or the announcement of a forthcoming offer or solicitation or invitation of any offer to buy any securities or the announcement of a forthcoming solicitation or invitation of any offer to buy any securities in any jurisdiction, including the United States, Australia, Canada or Japan. No securities are offered by or on behalf of AlzChem Group AG. This release and the information it contains are not for publication in any jurisdiction in which it would be unlawful.
In line with foreign securities laws, particularly the US Securities Act of 1933, as amended ("Securities Act"), shares of AlzChem Group AG have not been registered and will not be registered with foreign securities authorities and in particular may not be offered or sold in the United States of America ("USA") without registration or an exemption from the registration requirements of the Securities Act. This announcement may not be disseminated in the USA and/or within the USA and may not be distributed or forwarded to publications that are widely available in the USA.
In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.